MBBCh(Hons) MRCP(Rheum) PhD
Bye-Fellow; Director of Studies in Medicine
Director of Studies, Emmanuel College; Consultant Rheumatologist, Addenbrooke's Hospital; Director of the Rheumatology Research Unit, Addenbrooke's Hospital; Associate-PI, Department of Medicine; Theme Lead for E-learning, Clinical School for Medicine.
I have been a Consultant Rheumatologist, Director of the Rheumatology Research Unit, and lead for psoriatic arthritis (PsA) at Addenbrooke’s Hospital, Cambridge University Hospitals NHSFT since 2016. Having grown up in Cardiff, I graduated from the University of Wales College of Medicine in 2003, and then undertook clinical training in rheumatology and general internal medicine in Bath and Bristol between 2007 - 2015. I completed my PhD thesis on ‘biomarkers of psoriatic arthritis phenotypes’ at the Royal National Hospital for Rheumatic Diseases (University of Bath, UK) in 2015.
I have particular expertise in the investigation and management of psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA) and rheumatoid arthritis (RA). I am qualified in the use of musculoskeletal ultrasound to improve diagnostic accuracy, assessment of disease activity and to take ultrasound-guided synovial tissue biopsies from joints.
Undergraduate and post-graduate rheumatology clinical education.
My research interests include imaging (MRI, ultrasound and radiographic), genetic, serum-soluble and cellular biomarkers of psoriatic arthritis (PsA), ankylosing spondylitis (AS) and spondyloarthritis (SpA); in particular those that predict treatment response, prognosis and subphenotypes such as psoriatic spondyloarthritis and arthritis mutilans. I have researched the clinical and radiographic differences between PsA and AS, and juvenile- vs. adult-onset AS.
As Director of the Rheumatology Research Unit at Addenbrooke's Hospital, I lead on >10 phase 2a – 4 clinical studies of novel therapeutic agents for PsA, AS, rheumatoid arthritis and osteoarthritis. The research unit currently has >20 active clinical studies / trials including in addition SLE, Sjogren's, GCA, PMR, gout, and chronic pain.
The ability to apply stratified medicine and precision medicine in the management of patients with rheumatological disease has become particularly important given the young age at diagnosis (often aged 10-40 years), clinical impact (functional, social and work-productivity), and the increasing advanced therapies (conventional synthetic, targeted synthetic and biologic) that have emerged over the past two decades that are highly efficacious, potentially toxic and very high cost. The following paper by our group reviews these topics: https://www.nature.com/articles/s41584-020-00507-9
I am currently accepting PhD and MD students. My current students include:
1. Dr Joseph Hutton, PhD student & rheumatology trainee: investigating radiolabelled macrophage trafficking, synovial tissue pathotype and PBMCs in patients with psoriatic arthritis (PsA).
2. Dr Beverly Ng, PhD student & rheumatologist: investigating the stool microbiome before and after treatment in patients with psoriatic arthritis (PsA).
3. Dr Hannah Jethwa, MD student & rheumatology trainee: investigating serum-soluble bone-turnover biomarkers in patients with skin psoriasis as a predictor of developing psoriatic arthritis (PsA).
4. Dr Jobie Evans, MD student & rheumatologist: investigating the prevalence of axial spondyloarthritis (axSpA) in patients with Crohn's disease, and using magnetic resonance enterograms (MRE) to detect undiagnosed axSpA.
Past rheumatology fellows have studied:
-correlations between ultrasonography and clinical examination of the enthesis in psoriatic arthritis (Dr Mark Sapsford)
-multispecialty approaches in the management of psoriatic arthritis. Novel imaging techniques (ultrasound, MRI and high-resolution CT) in psoriatic arthritis. (Dr Tania Gudu).
-persistence of biologic therapies in psoriatic arthritis.
Further publications: https://pubmed.ncbi.nlm.nih.gov/?term=jadon+d